CELL THERAPEUTICS INC
10-Q/A, EX-27.1, 2000-09-11
PHARMACEUTICAL PREPARATIONS
Previous: CELL THERAPEUTICS INC, 10-Q/A, 2000-09-11
Next: CELL THERAPEUTICS INC, 10-Q/A, 2000-09-11



<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM MARCH 31,
2000 FORM 10-Q/A AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                      29,891,732
<SECURITIES>                                22,461,839
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            54,209,771
<PP&E>                                      16,580,220
<DEPRECIATION>                              11,959,891
<TOTAL-ASSETS>                              93,799,203
<CURRENT-LIABILITIES>                       11,174,268
<BONDS>                                              0
                                0
                                  2,366,625
<COMMON>                                   230,194,315
<OTHER-SE>                                (152,169,389)
<TOTAL-LIABILITY-AND-EQUITY>                93,799,203
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                               11,354,969
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             195,838
<INCOME-PRETAX>                            (11,195,468)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (11,195,468)
<EPS-BASIC>                                       (.58)
<EPS-DILUTED>                                     (.58)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission